ondansetron has been researched along with Cardiac Diseases in 2 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Gallegos-Castorena, S | 1 |
Martínez-Avalos, A | 1 |
Mohar-Betancourt, A | 1 |
Guerrero-Avendaño, G | 1 |
Zapata-Tarrés, M | 1 |
Medina-Sansón, A | 1 |
Kosmidis, PA | 1 |
Kalofonos, HP | 1 |
Christodoulou, C | 1 |
Syrigos, K | 1 |
Makatsoris, T | 1 |
Skarlos, D | 1 |
Bakogiannis, C | 1 |
Nicolaides, C | 1 |
Bafaloukos, D | 1 |
Bamias, A | 1 |
Samantas, E | 1 |
Xiros, N | 1 |
Boukovinas, I | 1 |
Fountzilas, G | 1 |
Dimopoulos, MA | 1 |
2 trials available for ondansetron and Cardiac Diseases
Article | Year |
---|---|
Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin.
Topics: Adolescent; Amifostine; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; | 2007 |
Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2008 |